CE-355621

• Description:

  CE-355621 is a humanized anti-c-Met IgG1 monoclonal antibody. CE-355621 can effectively bind with human c-Met (KD = 200 pM, IC50 = 466 pM) in A549 cells and cyno c-Met (KD = 610 pM) in cynomolgus kidney cells. CE-355621 inhibits the c-Met signaling pathway by blocking HGF binding. CE-355621 significantly inhibits the growth of tumors dependent on the c-Met/HGF pathway. CE-355621 can be used for research on cancer such as glioblastoma and gastric cancer[1][2].

• UNSPSC:

  12352203

• Target:

  C-Met/HGFR

• Related Pathways:

  Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• References & Citations:

  [1]Michaud NR, et al. Biochemical and pharmacological characterization of human c-Met neutralizing monoclonal antibody CE-355621. MAbs. 2012 Nov-Dec;4 (6) :710-23.|[2]Tseng JR, et al. Preclinical efficacy of the c-Met inhibitor CE-355621 in a U87 MG mouse xenograft model evaluated by 18F-FDG small-animal PET. J Nucl Med. 2008 Jan;49 (1) :129-134.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Inhibitory Antibodies

• Clinical Information:

  No Development Reported

• Isoform:

  Met